| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Alpha Tau Medical Ltd. | Alpha DaRT - (IMPACT) | Pancreatic ductal adenocarcinoma (PDAC) | Phase 3 | Intratumoral | Oncology | |
| Alpine Immune Sciences Inc. | N91115 | Cystic Fibrosis | Phase 2 | Trial Discontinued | Oral | Respiratory |
| Alpine Immune Sciences Inc. | ALPN-303 - (DENALI) | Systemic lupus erythematosus (SLE) | Phase 2 | Trial Planned | subcutaneous | Immunology |
| Alpine Immune Sciences Inc. | Acazicolcept (ALPN-101) - (SYNERGY) | Systemic Lupus Erythematosus (SLE) | Phase 2 | Ongoing | Intravenous | Immunology |
| Altamira Therapeutics Ltd. | AM-125 - (TRAVERS) | Vertigo | Phase 2 | Data Released | intranasal | Neurology |
| Alterity Therapeutics Limited | ATH434-202 - (biomarker data) | Multiple System Atrophy (MSA) | Phase 2 | Data Released | Oral | Neurology |
| Alterity Therapeutics Limited | ATH434-201 | Multiple System Atrophy (MSA) | Phase 2 | Data Released | oral | Neurology |
| Altimmune Inc. | Pemvidutide - (RESTORE) | Alcohol-Associated Liver Disease (ALD) | Phase 2 | Enrollment Initiation | Subcutaneous | Gastroenterology |